Bio-Matrix Scientific Group's Regen BioPharma Retains Cook General Biotechnology for Contract Manufacturing of HemaXellerate I
(firmenpresse) - SAN DIEGO, CA -- (Marketwired) -- 10/31/13 -- Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) announced today that Regen BioPharma Inc. (a subsidiary of BMSN) is initiating the production of clinical-grade HemaXellerate I using the Good Manufacturing Practices (GMP)-compliant contract manufacturer Cook General Biotechnology. The initial batches will be utilized for completing preclinical experiments requested by the FDA for IND # #15376 for a clinical trial using HemaXellerate I as a therapeutic for treatment resistant aplastic anemia. HemaXellerate I is a personalized stem cell treatment that utilizes fat derived cells to inhibit the biological processes responsible for aplastic anemia.
"We are excited to work with the team at Regen BioPharma in producing clinical grade HemaXellerate I, initially for preclinical studies, and subsequently for the clinical trial itself," said Erik J Woods, Ph.D., CEO of Cook General Biotechnology.
Cook General Biotechnology is dedicated to advancing the science and practical application of processing, storage, and manufacturing of cells and tissues to empower new cell-based medical therapies.
"Dr. Woods and the team at Cook General Biotechnology have previously guided cell therapy companies from preclinical to clinical stages in a variety of therapeutic areas. We are enthusiastic to work with this team at bringing HemaXellerate I to patients as quickly as possible," said David Koos, Chairman & CEO of Regen BioPharma, Inc.
Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN), is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. For more information refer to the company's website
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact:
Bio-Matrix Scientific Group, Inc. and
Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
619-702-1404
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 31.10.2013 - 15:35 Uhr
Sprache: Deutsch
News-ID 311481
Anzahl Zeichen: 0
contact information:
Town:
SAN DIEGO, CA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 291 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bio-Matrix Scientific Group's Regen BioPharma Retains Cook General Biotechnology for Contract Manufacturing of HemaXellerate I"
steht unter der journalistisch-redaktionellen Verantwortung von
Bio-Matrix Scientific Group, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
